{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:30:01Z","timestamp":1725409801659},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pregnant women are more likely to have a higher severity of illness after being infected with coronavirus disease 2019 compared with the general population, particularly in the hyperinflammatory phase. However, immunomodulatory drugs are contraindicated and have been associated with an increased risk of fetal abnormalities. Therefore, we are reporting our experience with the use of HA330 hemoperfusion in combination with standard therapy in severe to critical coronavirus disease 2019 cases among pregnant patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>From January 2020 to December 2021, four pregnant Thai women were treated with hemoperfusion using a cytokine adsorptive technique. The patients\u2019 ages ranged from 21 to 36\u00a0years old, and their gestational ages at the time of admission ranged from 18 to 38\u00a0weeks. Two patients required intubation. Extracorporeal blood purification with an adsorptive cartridge (HA330<jats:sup>\u00ae<\/jats:sup>, Jafron, China) was applied as an adjunctive strategy to standard therapy approximately one week after the onset of symptoms, and most patients received three sessions of hemoperfusion. The baseline C-reactive protein level was greater than 80\u00a0mg\/dL. The results showed that hemoperfusion could decrease the C-reactive protein level by approximately 80% and improve oxygenation. The newborns were delivered by Cesarean section without complications. Neither mortality nor serious adverse events related to hemoperfusion occurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This report may help ensure the use of the hemoperfusion strategy in pregnant patients during a cytokine storm. However, a larger cohort is needed to confirm its safety and efficacy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04726-6","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:02:17Z","timestamp":1725321737000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Add-on hemoperfusion in SARS-CoV-2-infected pregnant patients: a case series"],"prefix":"10.1186","volume":"18","author":[{"given":"Supattra","family":"Chiewroongroj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thummaporn","family":"Naorungroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranistha","family":"Ratanarat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"13","key":"4726_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239\u201342.","journal-title":"JAMA"},{"issue":"2","key":"4726_CR2","first-page":"461","volume":"104","author":"JB Nachega","year":"2020","unstructured":"Nachega JB, Sam-Agudu NA, Budhram S, Taha TE, Vannevel V, Somapillay P, et\u00a0al. Effect of SARS-CoV-2 infection in pregnancy on maternal and neonatal outcomes in Africa: an AFREhealth call for evidence through multicountry research collaboration. Am J Trop Med Hyg. 2020;104(2):461\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"4726_CR3","doi-asserted-by":"publisher","first-page":"575197","DOI":"10.3389\/fimmu.2020.575197","volume":"11","author":"B Abu-Raya","year":"2020","unstructured":"Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal immunological adaptation during normal pregnancy. Front Immunol. 2020;11:575197.","journal-title":"Front Immunol"},{"key":"4726_CR4","doi-asserted-by":"publisher","first-page":"103122","DOI":"10.1016\/j.jri.2020.103122","volume":"139","author":"H Liu","year":"2020","unstructured":"Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J Reprod Immunol. 2020;139:103122.","journal-title":"J Reprod Immunol"},{"key":"4726_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ajem.2022.03.060","volume":"56","author":"H Wang","year":"2022","unstructured":"Wang H, Li N, Sun C, Guo X, Su W, Song Q, et\u00a0al. The association between pregnancy and COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022;56:188\u201395.","journal-title":"Am J Emerg Med"},{"issue":"10229","key":"4726_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et\u00a0al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"key":"4726_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev-pathol-011110-130158","volume":"6","author":"MA Matthay","year":"2011","unstructured":"Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147\u201363.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"4726_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846\u20138.","journal-title":"Intensive Care Med"},{"key":"4726_CR9","unstructured":"Bhimraj AMR, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT, Muller WJ, Nakamura MM, O\u2019Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Infectious Diseases Society of America 2023; Version 11.0.0. 2023. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/. Accessed 22 Apr 2023."},{"issue":"4","key":"4726_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000492379","volume":"46","author":"A Bonavia","year":"2018","unstructured":"Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical utility of extracorporeal cytokine hemoadsorption therapy: a literature review. Blood Purif. 2018;46(4):337\u201349.","journal-title":"Blood Purif"},{"key":"4726_CR11","unstructured":"Blood Purification Devices EUAs. US Food and Drug Administration: FDA 2020. 2023. https:\/\/www.fda.gov\/emergency-preparedness-and-response. Accessed 22 Apr 2023."},{"issue":"2","key":"4726_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/hdi.12982","volume":"26","author":"H Mikaeili","year":"2022","unstructured":"Mikaeili H, Taghizadieh A, Nazemiyeh M, Rezaeifar P, Zununi Vahed S, Safiri S, et\u00a0al. The early start of hemoperfusion decreases the mortality rate among severe COVID-19 patients: a preliminary study. Hemodial Int. 2022;26(2):176\u201382.","journal-title":"Hemodial Int"},{"issue":"1","key":"4726_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000524606","volume":"52","author":"I Alavi Darazam","year":"2023","unstructured":"Alavi Darazam I, Kazempour M, Pourhoseingholi MA, Hatami F, Rabiei MM, Javandoust Gharehbagh F, et\u00a0al. Efficacy of hemoperfusion in severe and critical cases of COVID-19. Blood Purif. 2023;52(1):8\u201316.","journal-title":"Blood Purif"},{"key":"4726_CR14","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.nmni.2021.100937","volume":"44","author":"A Soleimani","year":"2021","unstructured":"Soleimani A, Taba SMM, Hasibi Taheri S, Loghman AH, Shayestehpour M. The effect of hemoperfusion on the outcome, clinical and laboratory findings of patients with severe COVID-19: a retrospective study. New Microbes New Infect. 2021;44:100937.","journal-title":"New Microbes New Infect"},{"issue":"11","key":"4726_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1159\/000521713","volume":"51","author":"K Surasit","year":"2022","unstructured":"Surasit K, Srisawat N. The efficacy of early additional hemoperfusion therapy for severe COVID-19 patients: a prospective cohort study. Blood Purif. 2022;51(11):879\u201388.","journal-title":"Blood Purif"},{"issue":"3","key":"4726_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/1744-9987.13948","volume":"27","author":"S Dianaty","year":"2023","unstructured":"Dianaty S, Khodadadi S, Alimoghaddam R, Mirzaei A. Comparison of outcomes and costs of extracorporeal blood purification therapies in critically ill COVID-19 patients. Ther Apher Dial. 2023;27(3):505\u201316.","journal-title":"Ther Apher Dial"},{"key":"4726_CR17","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Clinical management of COVID-19: Living guideline. Geneva: World Health Organization \u00a9 World Health Organization 2021; 2022."},{"issue":"1","key":"4726_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4269\/ajtmh.20-0442","volume":"103","author":"R Ratanarat","year":"2020","unstructured":"Ratanarat R, Sivakorn C, Viarasilpa T, Schultz MJ. Critical care management of patients with COVID-19: early experience in Thailand. Am J Trop Med Hyg. 2020;103(1):48\u201354.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 1","key":"4726_CR19","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1093\/cid\/ciab344","volume":"73","author":"JY Ko","year":"2021","unstructured":"Ko JY, DeSisto CL, Simeone RM, Ellington S, Galang RR, Oduyebo T, et\u00a0al. Adverse pregnancy outcomes, maternal complications, and severe illness among US delivery hospitalizations with and without a coronavirus disease 2019 (COVID-19) diagnosis. Clin Infect Dis. 2021;73(Suppl 1):S24-s31.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4726_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290343","volume":"18","author":"APB Dos Santos","year":"2023","unstructured":"Dos Santos APB, Vicente CR, Cola JP, Tanaka LF, Garbin JRT, Dell\u2019Antonio LS, et\u00a0al. The impact of COVID-19 on maternal death and fetal death, a cohort study in Brazil. PLoS ONE. 2023;18(8): e0290343.","journal-title":"PLoS ONE"},{"key":"4726_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3320","volume":"370","author":"J Allotey","year":"2020","unstructured":"Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et\u00a0al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370: m3320.","journal-title":"BMJ"},{"issue":"44","key":"4726_CR22","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","volume":"69","author":"LD Zambrano","year":"2020","unstructured":"Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et\u00a0al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status\u2014United States, January 22\u2013October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"4726_CR23","doi-asserted-by":"publisher","DOI":"10.2196\/31579","volume":"5","author":"J Muthuka","year":"2022","unstructured":"Muthuka J, Kiptoo M, Oluoch K, Nzioki JM, Nyamai EM. Association of pregnancy with coronavirus cytokine storm: systematic review and meta-analysis. JMIR Pediatr Parent. 2022;5(4): e31579.","journal-title":"JMIR Pediatr Parent"},{"issue":"8","key":"4726_CR24","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1590\/S0100-879X2004000800017","volume":"37","author":"KB Brosnihan","year":"2004","unstructured":"Brosnihan KB, Neves LA, Anton L, Joyner J, Valdes G, Merrill DC. Enhanced expression of Ang-(1\u20137) during pregnancy. Braz J Med Biol Res. 2004;37(8):1255\u201362.","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"4726_CR25","doi-asserted-by":"publisher","first-page":"R1953","DOI":"10.1152\/ajpregu.90592.2008","volume":"295","author":"A Levy","year":"2008","unstructured":"Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C. ACE2 expression and activity are enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2008;295(6):R1953\u201361.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"4726_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.5471","volume":"251","author":"AR Bourgonje","year":"2020","unstructured":"Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et\u00a0al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228\u201348.","journal-title":"J Pathol"},{"key":"4726_CR27","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda: National Institutes of Health (US); 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570371\/. Accessed 22 Apr 2023."},{"issue":"1","key":"4726_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmi.2021.08.016","volume":"28","author":"SCJ Jorgensen","year":"2022","unstructured":"Jorgensen SCJ, Lapinsky SE. Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review. Clin Microbiol Infect. 2022;28(1):51\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"4726_CR29","unstructured":"Olumiant. Amsterdam: The European Medicines Agency (EMA). 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed 22 Apr 2023."},{"key":"4726_CR30","unstructured":"Cytokine adsorption devices for treating respiratory failure in people with COVID-19. Manchester: The National Institute for Health and Care Excellence. https:\/\/www.nice.org.uk\/advice\/mib217\/resources\/cytokine-adsorption-devices-for-treating-respiratory-failure-in-people-with-covid19-pdf-2285965456587205. Accessed 22 Apr 2023."},{"issue":"23","key":"4726_CR31","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et\u00a0al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445\u201352.","journal-title":"JAMA"},{"issue":"14","key":"4726_CR32","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et\u00a0al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"key":"4726_CR33","first-page":"1","volume":"17","author":"D Schaedler","year":"2013","unstructured":"Schaedler D, Porzelius C, J\u00f6rres A, Marx G, Meier-Hellmann A, Putensen C, et\u00a0al. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. Crit Care. 2013;17:1\u2013200.","journal-title":"Crit Care"},{"issue":"10","key":"4726_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187015","volume":"12","author":"D Sch\u00e4dler","year":"2017","unstructured":"Sch\u00e4dler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et\u00a0al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE. 2017;12(10): e0187015.","journal-title":"PLoS ONE"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04726-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04726-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04726-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:02:27Z","timestamp":1725321747000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04726-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4726"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04726-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Siriraj Hospital Medical Research Ethics Committee, Mahidol University, Thailand (approval number Si-355\/2020). Written informed consent was obtained from the patients for publication of the details of their medical case (this consent may be obtained retrospectively).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}